Searched for
CIPLA EARNINGS REPORT
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- NLC India shares rally 18% to fresh record high after Q4 net profit skyrockets 189% YoYNLC India shares rose to a record high on Thursday after the company posted a 189% YoY surge in Q4 net profit to Rs 1,394 crore. Revenue ro...
- Iran war halts but missiles would echo in Q4 results: 40 stocks may report over 20% profit dipIndia's corporate earnings for the quarter ended March 2026 are feeling the economic heat from the recent Israel-US-Iran conflict. While so...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India salesDrug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
- Cipla gains 3% on USFDA nod to market Lanreotide"This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipel...
- Analysts expect Cipla to return up to 30% from here on as India biz gains momentumKotak Securities said the expansion of the Covid portfolio would support near-term earnings while the continued rollout of respiratory fran...
- Neutral on Cipla, target price Rs 840: Motilal OswalCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 72908.31 Crore) operating in Pharmaceuticals s...
- Brokerages raise targets on CiplaCipla’s shares hit a record high of Rs 814.45 on Monday before ending at Rs 795.65, up 9.2 per cent from the previous close. Cipla reported...
- Buy Cipla, target price Rs 523: Nirmal BangTthe brokerage has downward revised its FY21 and FY22 forecasts on Cipla, having knocked off Voltaren sales number and pushed Albuterol inh...
- Brokerages slash Cipla’s target price on weak Q4 earningsCipla reported a consolidated net loss of Rs 61.8 crore for the quarter ended March.
- Cipla posts 44% rise in Q2 net profit; India sales flatIn the past quarter, Cipla posted Rs 3,452 crore of revenue, compared with Rs 2,767 crore a year earlier.
- Nomura lowers Cipla’s rating on high valuation, earnings concernsNomura has set a price target of Rs 569 for the stock, implying 9% potential downside from the Thursday’s closing price of Rs 622.
Load More
